The company provides integrated, end-to-end new drug development and production services for the global pharmaceutical and life science industry, and has operating bases in Asia, Europe, North America, etc. Through its unique “CRDMO” business model, Pharmacovigant continuously lowers the R&D threshold, helps customers improve R&D efficiency, and brings more breakthrough treatment plans to patients. The scope of services covers fields such as chemical drug development and production, biological research, pre-clinical testing, and clinical trial research. The company's main business is to provide integrated, end-to-end new drug development and production services for the global pharmaceutical and life science industry. Company honors include Baihua Association's “Enterprise of the Year Award”, Sina Pharmaceuticals's “Most Influential Enterprise in China's Pharmaceutical Industry”, and “China's 100 Model Employers” for four consecutive years.